Do TNF-α Inhibitors Reduce Spinal Inflammation, do they have Effect on Radiographic Progression? A randomized, multicenter, double-blind, placebo-controlled study demonstrated that adalimumab ...

TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the ...

Isomyosamine is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

Isomyosamine is an oral, next-generation TNF-a inhibitor with the potential to transform the way TNF-a based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

TNF Pharmaceuticals (TNFA) announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha inhibitor drug ...

At 12 months, 25.1% of patients starting tofacitinib and 30.1% of TNF inhibitor initiators achieved low disease activity. Tofacitinib and TNF inhibitors are common options when methotrexate proves ...

which promotes the release of soluble TNF from its membrane-bound precursor. Inhibitors of this enzyme with drug-like properties have been made and tested in the clinic. These inhibitors include ...

BALTIMORE, February 25, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed ...